Ken Griffin Protara Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.4 $510 - $720	300 Added 20.0%	1,800 $3,000
Q2 2024 Aug 14, 2024	SELL	$1.96 - $4.14 $1,372 - $2,898	-700 Reduced 31.82%	1,500 $3,000
Q1 2024 May 15, 2024	BUY	$1.86 - $4.83 $3,720 - $9,660	2,000 Added 1000.0%	2,200 $8,000
Q4 2023 Feb 14, 2024	SELL	$1.12 - $1.93 $896 - $1,544	-800 Reduced 80.0%	200 $0
Q3 2023 Nov 14, 2023	BUY	$1.64 - $2.93 $1,312 - $2,344	800 Added 400.0%	1,000 $1,000
Q2 2023 Aug 14, 2023	SELL	$2.27 - $3.59 $1,135 - $1,795	-500 Reduced 71.43%	200 $0
Q4 2022 Feb 14, 2023	BUY	$2.43 - $3.7 $1,701 - $2,590	700 New	700 $1,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $26.9M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.